The ADC technology market offers growth opportunities driven by increased demand for targeted oncology therapies and advancements in conjugation and linker technologies. Strategic partnerships and ...
AsymBio’s Conjugation Toolbox supports customized process development across both random and site-specific conjugation technologies.For ...
Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The ...
These complex biomolecules are specifically engineered to selectively deliver therapeutic agents to target cells by linking them to monoclonal antibodies. The safety profile and effectiveness of ADCs ...
Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to ...
ST. LOUIS, Oct. 14, 2013 -- Sigma-Aldrich Corporation's (SIAL) custom manufacturing services business unit, SAFC® Commercial (www.sigma-aldrich.com/safc), is ...
ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies ...
Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...
ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution ...
ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results